Data Supplement

• Supplemental Figures -

  Supplemental Figure 1.  Sensitivity analysis on multiplication factors of S-warfarin PBPK model without TMDD mechanism in subjects with CYP2C9 *1/*1 when warfarin is administered alone.

  Supplemental Figure 2. Sensitivity analysis on multiplication factors of S-warfarin PBPK model with TMDD mechanism in subjects with CYP2C9 *1/*1 when warfarin is administered alone.

  Supplemental Figure 3. Sensitivity analysis on multiplication factors of R-warfarin PBPK model without TMDD mechanism in subjects with CYP2C9 *1/*1 when warfarin is administered alone.

  Supplemental Figure 4. Sensitivity analysis on multiplication factors of R-warfarin PBPK model with TMDD mechanism in subjects with CYP2C9 *1/*1 when warfarin is administered alone.

  Supplemental Figure 5. Validation of fluconazole model predictions.

  Supplemental Figure 6. Validation of rifampin model predictions.

• Supplemental Material 2 -

  Supplemental Material 2. S-warfarin PBPK model mrgsolve model file. 

• Supplemental Material 3 -

  Supplemental Material 3. S-warfarin PBPK model with fluconazole inhibition mrgsolve model file.
  

• Supplemental Material 4 -

  Supplemental Material 4. S-warfarin PBPK model with rifampin induction mrgsolve model file.
  

• Supplemental Material 5 -

  Supplemental Material 5. R-warfarin PBPK model mrgsolve model file.
  

• Supplemental Material 6 -

  Supplemental Material 6. R-warfarin PBPK model with fluconazole inhibition mrgsolve model file.

• Supplemental Material 7 -

  Supplemental Material 7. R-warfarin PBPK model with rifampin induction mrgsolve model file.